Volume 13, Issue 2

Mira K. Desai, Jigar Dilipkumar Kapadia

pp. 113–118 · DOI: 10.1177/0976500X221111448 · 2022

Frequent media reports of disputes between medical teachers, resident doctors, and patients have been disturbing thus indicating an increasing gap and decline in the values of the profession. The foundation of medical pr…

Dhanaraj Manoharan, Ravi Vignesh N., Srinivasan Shreya, Saravanan Suzsmi L.

pp. 119–124 · DOI: 10.1177/0976500X221105921 · 2022

Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types,…

G. S. Swarna Bindu, Dithu Thekkekkara, T. Lakshmi Narayanan, Jiju Narayanan, Sri Harsha Chalasani, S. N. Manjula

pp. 125–134 · DOI: 10.1177/0976500X221107503 · 2022

Cognitive decline is a late adverse event in brain tumor survivors. The patients receiving radiation treatment exhibit a wide range of damage and impairment in attention, memory, and executive function compared to the un…

S. K. Md. Jasmine, Vidya Sagar Reddy G., Neelima Gorityala, Someswar Rao Sagurthi, Sandhya Mungapati, Kota Neela Manikanta, Uday Sankar Allam

pp. 135–147 · DOI: 10.1177/0976500X221109721 · 2022

Objective: To computationally model the CTX-M-5 β-lactamase and establish its structure, which is exclusively present in human-associated Salmonella. Methods: The CTX-M-5 aminoacid sequence (Uniprot ID:O65975) of Salmone…

Wan Failiza Wan Mohamad Fazil, Azimah Amanah, Muhammad Asyraf Abduraman, Shaida Fariza Sulaiman, Habibah Abdul Wahab, Mei Lan Tan

pp. 148–159 · DOI: 10.1177/0976500X221114003 · 2022

Objective: To determine the effects of deoxyelephantopin on mTOR and its related target molecules (Akt/mTOR/P70S6K) in the ER-positive breast cancer cell line. Materials and Methods: Primary in silico simulations were de…

Mohammed Farhan, Prathvi Rani, Fatimazahra Moledina, Thomas George, Hari Prabhath Tummala, Surulivelrajan Mallayasamy

pp. 160–166 · DOI: 10.1177/0976500X221111455 · 2022

Objectives: To build a lamotrigine (LTG) physiologically based pharmacokinetic (PBPK) model (LTG PBPK) and compare it to the clinical data from South Asian Indian patients and use this model to understand the drug intera…

Rajat Shah, Shefali Thanawala, Ramapalaniappan Abiraamasundari

pp. 167–174 · DOI: 10.1177/0976500X221111669 · 2022

Objectives: To evaluate the pharmacokinetics of a novel sustained-release oral tablet (C-Fence, Inventia Healthcare Limited, Mumbai, India). Methods: We conducted a randomized, placebo-controlled, parallel-design, 500 mg…

Kiran Belur, Prema Arunachalam, Jamuna Rani Raveendran

pp. 175–181 · DOI: 10.1177/0976500X221105760 · 2022

Objectives: To compare the serum vitamin D and serum cathelicidin antimicrobial peptide (CAMP) levels among tuberculosis patients and healthy subjects and to determine the association between serum vitamin D and cathelic…

Apoorva Devarahosahally Shivanna, Reena R. Kadni, Syed Farzan Tausif, Varghese K. Zachariah

pp. 182–189 · DOI: 10.1177/0976500X221105758 · 2022

Objective: To compare the prophylactic antiemetic efficacy of ondansetron monotherapy with that of the combination of ondansetron and dexamethasone in the prevention on postoperative nausea and vomiting (PONV) in breast …

İbrahim Yilmaz, Numan Karaarslan, Hakan Somay, Hanefi Ozbek, Ozkan Ates

pp. 190–196 · DOI: 10.1177/0976500X221112479 · 2022

Objective: To find out whether curcumin can be effective in the treatment of traumatic brain injury (TBI). Methods: A comprehensive and systematic literature search in the PubMed electronic database was performed. Descri…

Smrati Tiwari, Zahaan Vakil

pp. 197–202 · DOI: 10.1177/0976500X221105759 · 2022

Objectives: To determine the incidence and frequency of adverse drug reactions (ADRs) to find out factors, if any contributing to the same, while also exploring the use of amphotericin B deoxycholate as a cheaper and saf…

Himadri Sekhar Dasgupta, Debashis Priyadarshan Sahoo, Bhupen Barman, Dhriti Brahma

pp. 203–206 · DOI: 10.1177/0976500X221107494 · 2022

Tramadol is a weak mu (µ) opioid receptor agonist that acts by inhibiting serotonin and norepinephrine uptake. Tramadol undergoes extensive hepatic metabolism by a number of pathways, including CYP2D6 and CYP3A4, and by …